feedback

Course Director

Adam Brufsky, MD, PhD
Adam Brufsky, MD, PhD

Comprehensive Cancer Center
UPMC Hillman Cancer Center
Magee Women’s Hospital
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Faculty

Angelo Di Leo
Angelo Di Leo, MD, PhD

Hospital of Prato, AUSL Toscana Centro
Prato, Italy

Prof. Miguel Martin
Prof. Miguel Martin

Hospital General Universitario Gregorio Marañón
Universidad Complutense
Madrid, Spain

Accredited by

Medical Learning Institute, Inc.

Activity Description

In this activity, breast cancer experts review the latest findings from randomized clinical trials as well as real-world studies assessing CDK 4/6 inhibitors in the management of patients with HR-positive, HER2-negative breast cancer, and discuss the complementary nature of clinical and real-world research and how data from both sources add to the body of evidence on this therapeutic class that helps inform clinical practice.

Target Audience

This activity has been designed to meet the educational needs of oncologists and other clinicians involved in the management of patients with breast cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Discuss real-world evidence derived from real-world data supplementing clinical trial evidence related to the benefits and risks of CDK 4/6 inhibitors in metastatic breast cancer
  • Establish best practices for analyzing and interpreting real-world data in addition to data collected from clinical trials related to CDK 4/6 inhibitors in metastatic breast cancer in terms of study design, validity, data sources, and implications for everyday oncology practice
  • Implement appropriate clinical decisions regarding the selection and use of CDK 4/6 inhibitors in the treatment of patients with metastatic breast cancer informed by the latest real-world and clinical trial evidence

Providership, Credit, and Support


This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from Pfizer.

Physician Continuing Medical Education

ACCMEThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Faculty Disclosures

Chair
Adam Brufsky, MD, PhD
Professor of Medicine
Co-Director, Comprehensive Cancer Center
UPMC Hillman Cancer Center
Magee Women’s Hospital
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Adam Brufsky, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Eli Lilly and Company; and Novartis Pharmaceuticals Corporation.

Faculty
Angelo Di Leo, MD, PhD
“Sandro Pitigliani” Department of Medical Oncology
Hospital of Prato, AUSL Toscana Centro
Prato, Italy

Angelo Di Leo, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Eli Lilly and Company; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; and Seattle Genetics.
Speakers Bureau participant with Eli Lilly and Company; and Novartis Pharmaceuticals Corporation.

Prof. Miguel Martin, MD, PhD
Professor of Medicine
Head, Medical Oncology Service
Hospital General Universitario Gregorio Marañón
Universidad Complutense
Madrid, Spain

Prof. Miguel Martin, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Puma Biotechnology, Inc.; and Taiho Oncology, Inc.
Grant/Research Support from AstraZeneca; F. Hoffmann-La Roche Ltd; Novartis Pharmaceuticals Corporation; and Puma Biotechnology, Inc.
Other Financial or Material Support as a speaker for Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Pfizer Inc.; and Puma Biotechnology, Inc.

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewer has nothing to disclose:

Reid W. Merryman, MD

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.